PE20000126A1 - Composicion para tratar enfermedades respiratorias y de la piel - Google Patents

Composicion para tratar enfermedades respiratorias y de la piel

Info

Publication number
PE20000126A1
PE20000126A1 PE1998001265A PE00126598A PE20000126A1 PE 20000126 A1 PE20000126 A1 PE 20000126A1 PE 1998001265 A PE1998001265 A PE 1998001265A PE 00126598 A PE00126598 A PE 00126598A PE 20000126 A1 PE20000126 A1 PE 20000126A1
Authority
PE
Peru
Prior art keywords
phenyl
composition
ephinasten
acid
skin
Prior art date
Application number
PE1998001265A
Other languages
English (en)
Inventor
Peder K Jensen
Richard R Lorber
Melvyn R Danzig
Paul T Medeiros
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20000126A1 publication Critical patent/PE20000126A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

QUE COMPRENDE a)UN ANTAGONISTA DEL LEUCOTRIENO DE PREFERENCIA MONTELUKAST, ACIDO 1-(((R)-(3-(2-(6,7-DIFLUORO-2-QUINOLINIL)ETENIL)FENIL)-3-(2-(2-HIDROXI-2-PROPIL)FENIL)TIO)METILCICLOPROPANOACETICO, ACIDO 1-(((1(R)-3-(3-(2-(2,3-DICLOROTIENO[3,2-b]PIRIDIN-5-IL)-(E)-ETENIL)FENIL-3-(2-(1-HIDROXI-1-METILETIL)FENIL)PROPIL)TIO)METIL)CICLOPROPANOACETICO, PRANLUKAST, ZAFIRLUKAST, ACIDO[2-[[2-(4-TERC-BUTIL-2-TIAZOLIL)-5-BENZOFURANIL]OXIMETIL]FENIL]ACETICO; b)UNA ANTIHISTAMINA TAL COMO DESCARBOETOXILORATADINA, CETIRIZINA, FEXOFENADINA, EBASTINA, ASTEMIZOL, NORASTEMIZOL, EPINASTINA, EFLETIRIZINA: TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN DESCONGESTIVO TAL COMO PSEUDOEFEDRINA, UN SUPRESOR DE LA TOS TAL COMO DEXTROMETORFANO, UN EXPECTORANTE/MUCOLITICO TAL COMO GUAIFENESINA, UN ANALGESICO. LA COMPOSICION PUEDE SER UTIL EN EL TRATAMIENTO DE ENFERMEDADES DE LA PIEL, TRACTO RESPIRATORIO, SINTOMAS ASOCIADOS COMO ESTORNUDO, PICAZON, GOTEO DE LA NARIZ, CONGESTION NASAL, ENROJECIMIENTO DE LOS OJOS, LAGRIMEO, PICAZON EN LA PIEL, DOLORES DE CABEZA, DOLORES PERSISTENTES Y DOLORES ASOCIADOS CON LA RINITIS ALERGICA, ASMA
PE1998001265A 1997-12-23 1998-12-22 Composicion para tratar enfermedades respiratorias y de la piel PE20000126A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6863897P 1997-12-23 1997-12-23
US7863898P 1998-03-19 1998-03-19

Publications (1)

Publication Number Publication Date
PE20000126A1 true PE20000126A1 (es) 2000-02-23

Family

ID=26749192

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001265A PE20000126A1 (es) 1997-12-23 1998-12-22 Composicion para tratar enfermedades respiratorias y de la piel

Country Status (27)

Country Link
EP (1) EP1041990B1 (es)
JP (2) JP2001526232A (es)
KR (1) KR100737710B1 (es)
CN (1) CN1283115A (es)
AR (1) AR017224A1 (es)
AT (1) ATE331522T1 (es)
AU (1) AU758771B2 (es)
BR (1) BR9814417A (es)
CA (1) CA2315721C (es)
CO (1) CO4980868A1 (es)
CZ (1) CZ301349B6 (es)
DE (1) DE69835103T2 (es)
DK (1) DK1041990T3 (es)
ES (1) ES2263229T3 (es)
HK (1) HK1027502A1 (es)
HU (1) HUP0101369A3 (es)
ID (1) ID26390A (es)
IL (1) IL136461A0 (es)
MY (1) MY121744A (es)
NO (1) NO20003288L (es)
NZ (1) NZ520907A (es)
PE (1) PE20000126A1 (es)
PL (1) PL193131B1 (es)
PT (1) PT1041990E (es)
SA (1) SA99200013B1 (es)
SK (1) SK286103B6 (es)
WO (1) WO1999032125A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303632B1 (en) 1992-09-03 2001-10-16 Sepracor Inc. Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
ES2210957T3 (es) 1992-09-03 2004-07-01 Sepracor Inc. Composiciones farmaceuticas que contienen norastemizol.
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
IT1303671B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
EP1000623A1 (en) * 1998-09-29 2000-05-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Use of epinastine as antitussivum
US20020198246A1 (en) 1998-09-30 2002-12-26 Ono Pharmaceutical Co., Ltd. Agent for preventing and/or treating sinusitis
JP3627801B2 (ja) * 1998-09-30 2005-03-09 小野薬品工業株式会社 副鼻腔炎の予防および／または治療剤
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
CA2398261A1 (en) * 2000-02-03 2001-08-09 Schering Corporation Treating allergic and inflammatory conditions
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
JP2002087963A (ja) * 2000-09-08 2002-03-27 Nippon Boehringer Ingelheim Co Ltd 直接打錠により製造されたエピナスチン含有錠剤
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
JP4074427B2 (ja) * 2000-12-18 2008-04-09 株式会社栃木臨床病理研究所 子宮内膜症の予防又は治療薬
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
WO2003000264A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
US7014867B2 (en) 2001-06-28 2006-03-21 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
AU2003264859A1 (en) * 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
WO2003101437A2 (en) * 2002-05-29 2003-12-11 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
DE60319227T2 (de) * 2002-07-02 2009-05-07 Ucb Farchim S.A. Diarylmethylpiperazines als prophylaktische oder therapeutische mittel gegen virale myocarditis
AU2003288041A1 (en) * 2002-12-06 2004-06-30 Ucb Farchim, S.A. Tablet comprising efletirizine and pseudoephedrine
WO2004087095A2 (es) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositivo osmótico que contiene zafirlukast y un antagonista h1
EP1468696A1 (en) * 2003-04-17 2004-10-20 Boehringer Ingelheim International GmbH Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
EP1735001A2 (en) * 2004-03-24 2006-12-27 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
KR101801864B1 (ko) 2010-06-16 2017-11-27 인플래머토리 리스폰스 리서치, 아이엔씨. 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP6051378B2 (ja) * 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
WO2013058527A2 (ko) * 2011-10-18 2013-04-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
KR101278572B1 (ko) * 2011-10-18 2013-06-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
EP2969002B8 (en) 2013-03-13 2018-02-21 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US9636318B2 (en) * 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
KR102356601B1 (ko) 2014-06-10 2022-01-27 지엘팜텍주식회사 슈도에페드린을 함유하는 방출조절 펠렛 조성물
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US9981039B2 (en) 2015-05-29 2018-05-29 Accolade Pharma Llc Composition, its preparation and method of use in treating skin disorders
BR112018072164A2 (pt) * 2016-05-17 2019-02-12 Proponent Biotech Gmbh composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição
SG10202006016QA (en) * 2016-05-17 2020-07-29 Proponent Biotech Gmbh Carboxylic acid for treating/preventing nasal congestion
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
DE4203201A1 (de) * 1992-02-05 1993-08-12 Boehringer Ingelheim Kg Neue amidinderivate, ihre herstellung und verwendung
HU216191B (hu) * 1992-02-05 1999-05-28 Boehringer Ingelheim Kg Eljárás új amidinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
NZ331160A (en) * 1996-02-08 2000-07-28 Merck & Co Inc use of loratadine and a leukotriene antagonist to treat asthma
EP0954318A1 (en) * 1996-06-04 1999-11-10 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions

Also Published As

Publication number Publication date
HK1027502A1 (en) 2001-01-19
HUP0101369A3 (en) 2002-11-28
SA99200013B1 (ar) 2006-10-02
NZ520907A (en) 2004-05-28
BR9814417A (pt) 2000-10-10
NO20003288D0 (no) 2000-06-22
CA2315721C (en) 2008-08-12
IL136461A0 (en) 2001-06-14
SK286103B6 (sk) 2008-03-05
KR100737710B1 (ko) 2007-07-11
AU1907199A (en) 1999-07-12
NO20003288L (no) 2000-08-22
KR20010033485A (ko) 2001-04-25
JP2001526232A (ja) 2001-12-18
CA2315721A1 (en) 1999-07-01
ID26390A (id) 2000-12-21
AR017224A1 (es) 2001-08-22
DE69835103T2 (de) 2006-12-21
MY121744A (en) 2006-02-28
DK1041990T3 (da) 2006-10-02
HUP0101369A2 (hu) 2002-03-28
JP2011068679A (ja) 2011-04-07
ES2263229T3 (es) 2006-12-01
CZ301349B6 (cs) 2010-01-27
DE69835103D1 (de) 2006-08-10
ATE331522T1 (de) 2006-07-15
SK8972000A3 (en) 2001-02-12
EP1041990B1 (en) 2006-06-28
EP1041990A1 (en) 2000-10-11
PT1041990E (pt) 2006-10-31
CN1283115A (zh) 2001-02-07
CZ20002198A3 (cs) 2000-11-15
AU758771B2 (en) 2003-03-27
WO1999032125A1 (en) 1999-07-01
CO4980868A1 (es) 2000-11-27
PL193131B1 (pl) 2007-01-31
PL341343A1 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
PE20000126A1 (es) Composicion para tratar enfermedades respiratorias y de la piel
JP2001526232A5 (es)
CA2328073A1 (en) Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
CR8301A (es) Acidos 5-((fenoxialquilquil)tio)- fenoxiaceticos y analogos
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
RU2007138270A (ru) Комбинация антихолинергетиков и антагонистов лейкотриеновых рецепторов для лечения респираторных заболеваний и фармацевтическая композиция на ее основе
AR039891A1 (es) Compuestos tiofen-amidinas, sus composiciones farmaceuticas y su uso para la preparacion de medicamentos para tratar enfermedades y trastornos mediados por c1s
ECSP003836A (es) Composicion estable para dosis oral de liberacion extendida
JP2014501281A5 (es)
AR008293A1 (es) Composicion que comprende una cantidad antihistaminica para el tratamiento de las respuestas alergicas de las vias respiratorias superiores
DE3877904D1 (de) Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
EA200600433A1 (ru) Сопряжённые гетероциклические соединения
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
AR020660A1 (es) Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
BR0317370A (pt) Composição farmacêutica e método paliativo
ME00349B (me) Novi kristalni anhidrat sa antiholinergij skim dejstvom
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
BR0008934A (pt) Ëculos para maquilagem
WO2004098612A3 (en) Calcitriol analogs of uses thereof
RU2009144286A (ru) Составы с n-галогензамещенной аминокислотой и противовоспалительными соединениями
ATE326947T1 (de) Thixotropes nasenspray
BRPI0414534A (pt) ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos
CA2328074A1 (en) Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
WO2005073194A3 (en) Solid forms of montelukast acid

Legal Events

Date Code Title Description
FC Refusal